Float Short %

7.76

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

-0.35

EPS Last/This Y

EPS This/Next Y

0.1

Price

2.9

Target Price

4.33

Analyst Recom

Performance Q

6.02

Relative Volume

0.94

Beta

1.37

Ticker: PBYI

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	PBYI	3.02	0.02	0.25	2316
2025-01-24	PBYI	2.96	0.03	0.20	2401
2025-01-27	PBYI	2.97	0.03	1.54	2470
2025-01-28	PBYI	3.04	0.07	0.28	2615
2025-01-29	PBYI	3.07	0.08	0.00	2670
2025-01-30	PBYI	3.04	0.08	0.00	2715
2025-01-31	PBYI	2.88	0.08	0.00	2794
2025-02-03	PBYI	2.77	0.08	0.02	2805
2025-02-04	PBYI	2.82	0.07	0.02	2854
2025-02-05	PBYI	2.92	0.07	0.00	2960
2025-02-06	PBYI	2.88	0.07	0.00	2971
2025-02-07	PBYI	2.78	0.07	0.40	2976
2025-02-10	PBYI	2.79	0.07	0.00	2982
2025-02-11	PBYI	2.76	0.07	0.21	3007
2025-02-12	PBYI	2.8	0.07	0.11	3059
2025-02-13	PBYI	2.91	0.07	0.00	3067
2025-02-14	PBYI	2.86	0.07	0.80	3092
2025-02-18	PBYI	2.88	0.07	0.02	3092
2025-02-19	PBYI	2.88	0.07	0.00	3192
2025-02-20	PBYI	2.92	0.07	15.83	3192
2025-02-21	PBYI	2.9	0.17	0.10	3466
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	PBYI	3.02	-54.8	-	0.50
2025-01-24	PBYI	2.96	-54.8	-	0.50
2025-01-27	PBYI	2.98	-54.8	-	0.50
2025-01-28	PBYI	3.04	-54.8	-	0.50
2025-01-29	PBYI	3.07	-54.8	-	0.50
2025-01-30	PBYI	3.04	-54.8	-	0.50
2025-01-31	PBYI	2.88	-54.8	-	0.50
2025-02-03	PBYI	2.79	-54.8	-	0.50
2025-02-04	PBYI	2.82	-54.8	-	0.50
2025-02-05	PBYI	2.93	-54.8	-	0.50
2025-02-06	PBYI	2.89	-54.8	-	0.50
2025-02-07	PBYI	2.79	-54.8	-	0.50
2025-02-10	PBYI	2.78	-54.8	-	0.50
2025-02-11	PBYI	2.75	-54.8	-	0.50
2025-02-12	PBYI	2.80	-54.8	-	0.50
2025-02-13	PBYI	2.91	-54.8	-	0.50
2025-02-14	PBYI	2.86	-54.8	-	0.50
2025-02-18	PBYI	2.88	-54.8	-	0.50
2025-02-19	PBYI	2.88	-54.8	-	0.50
2025-02-20	PBYI	2.92	-54.8	-	0.50
2025-02-21	PBYI	2.90	-54.8	-	0.50
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	PBYI	-0.60	-3.90	8.62
2025-01-24	PBYI	-0.60	-3.90	8.62
2025-01-27	PBYI	-0.60	-3.84	8.62
2025-01-28	PBYI	-0.60	-3.84	8.81
2025-01-29	PBYI	-0.60	-3.84	8.81
2025-01-30	PBYI	-0.60	-3.84	8.81
2025-01-31	PBYI	-0.60	-3.84	8.81
2025-02-03	PBYI	-0.60	-3.74	8.81
2025-02-04	PBYI	-0.60	-3.74	8.81
2025-02-05	PBYI	-0.60	-3.74	8.81
2025-02-06	PBYI	-0.60	-3.74	8.81
2025-02-07	PBYI	-0.60	-3.74	8.81
2025-02-10	PBYI	-0.60	-5.72	8.81
2025-02-11	PBYI	-0.60	-5.72	8.81
2025-02-12	PBYI	-0.60	-5.72	8.54
2025-02-13	PBYI	-0.60	-5.72	8.54
2025-02-14	PBYI	-0.44	-5.72	8.55
2025-02-18	PBYI	-0.44	-5.63	8.63
2025-02-19	PBYI	-0.45	-5.63	8.43
2025-02-20	PBYI	-0.45	-5.63	8.43
2025-02-21	PBYI	-0.58	-5.63	7.76
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.41

Avg. EPS Est. Current Quarter

0.14

Avg. EPS Est. Next Quarter

0.06

Insider Transactions

-0.58

Institutional Transactions

-5.63

Beta

1.37

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

4.25

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-88.3

Target Price

4.33

P/E

6.12

Forward P/E

8.54

PEG

P/S

0.59

P/B

2.01

P/Free Cash Flow

4.23

EPS

0.47

Average EPS Est. Cur. Y

0.5

EPS Next Y. (Est.)

0.6

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

9.54

Relative Volume

0.94

Return on Equity vs Sector %

13.5

Return on Equity vs Industry %

29.1

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.06

EBIT Estimation

Puma Biotechnology Inc

Sector: Healthcare

Industry: Biotechnology

Employees: 185

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

stock quote shares PBYI – Puma Biotechnology, Inc. Stock Price stock today

news today PBYI – Puma Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch PBYI – Puma Biotechnology, Inc. yahoo finance google finance

stock history PBYI – Puma Biotechnology, Inc. invest stock market

stock prices PBYI premarket after hours

ticker PBYI fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PBYI

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y